Page last updated: 2024-11-05

troglitazone and Hematologic Malignancies

troglitazone has been researched along with Hematologic Malignancies in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Turturro, F1
Lawson, M1
Friday, E1
Welbourne, T1

Other Studies

1 other study available for troglitazone and Hematologic Malignancies

ArticleYear
Targeting the Na(+)/H(+) exchanger: an old concept with new perspectives in the treatment of hematological malignancies.
    Leukemia research, 2007, Volume: 31, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromans; Hematologic Neoplasms; Humans

2007